Phialogics AG

1. Executive Summary (Confidence: High)

Phialogics AG, founded in 2021 and based in Allschwil, Switzerland, is an innovative spin-off from the Fraunhofer Institute of Translational Medicine and Pharmacology (ITMP). The company is dedicated to providing disease-modifying solutions for patients with autoimmune conditions through a unique platform that modifies IgV domains to achieve unprecedented precision in immune modulation. In April 2023, the organization successfully closed a pre-seed financing round led by High-Tech Gründerfonds (HTGF) and has since been part of the BaseLaunch portfolio. Their technology targets the root cause of autoimmune tissue injury by replicating natural protein-protein interactions, moving away from systemic immunosuppression toward localized immune tolerance.